Practical combination therapy of Amlodin and angiotensin II Receptor blocker(ARB); safety and efficacy in paTieNts with hypERtension Study (PARTNER Study)

Practical combination therapy of Amlodin and angiotensin II Receptor blocker(ARB); safety and efficacy in paTieNts with hypERtension Study (PARTNER Study) - PARTNER Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005888

Enrollment

6000

Registered

2011-06-30

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects those who must satisfy the following conditions (1)Amlodin-naive-hypertensive patients who have been receiving antihypertensive therapy with ARB (2)ARB-naive-hypertensive patients who have been receiving antihypertensive therapy with Amlodin (3)Amlodin and ARB-naive-hypertensive patients

Exclusion criteria

Exclusion criteria: (1)Hypertensive Patients who had already received antihypertensive combination therapy with both Amlodin and ARB,and ARB-amlodipine combination agent, before the enrollment (2)Hypertensive patients who have received amlodipine preparation except Amlodin within 12 weeks of the enrollment

Design outcomes

Primary

Measure	Time frame
[Safety] The incidence of side effects(Primary endpoint) The incidences of serious adverse events [Efficacy] Change in blood pressure in the doctor's office(Primary endpoint) Defining the percentage of cases who achieved the guideline-oriented hypertensive treatment goal(Guideline for the management of hypertension 2009 established by The Japanese Society of Hypertension) [Other] Renal function	—

Countries

Japan

Contacts

Public ContactHirofumi Fukuda

Dainippon Sumitomo Pharma Co.,Ltd. Post Marketing Surveillance Department

hirofumi-1-fukuda@ds-pharma.co.jp06-6454-8113

Outcome results